Skip to content

Effect of Carica papaya leaf extract on Dengue Feve

Controlled trial on effect of Carica papaya leaf extract on patients with Dengue Fever

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2013/005
Enrollment
Unknown
Registered
2013-01-21
Start date
2013-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue fever

Interventions

Consenting patients will be randomized into treatment and control groups. The treatment group will be given Carica papaya leaf extract. The extract will be prepared by crushing fresh mature Papaya lea

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male and female patients admitted to the university medical unit at Colombo South Teaching Hospital fulfilling ALL the following criteria will be included in this study. (1) >18 and <60 years of age (2) Acute onset of fever (3) Platelet count <150,000 per cu.mm and / or Hct elevated by 5% and / or white cell count <5000/cu.mm. (4) Dengue IgM positive after 7 days of illness

Exclusion criteria

Exclusion criteria: (1) History of allergy to papaya (2)Pregnancy (3)Patients who have already taken papaya juice extracts before admitting to hospital (4) Patients with previously diagnosed abnormal clotting profile as per past history and medical records (5) Patients suffering from any other illnesses which will influence the course of dengue fever. (6) Patients suffering from any other illnesses or on drugs which will influence the bone marrow function or haemopoitic system. (7) Dengue patients who are being treated with blood products. (8) Patients with severe hemorrhagic dengue (9) Dengue IgM negative after 7 days of the illness

Design outcomes

Primary

MeasureTime frame
White blood cell count (WBC) / Differential counts [At recruitment and daily until discharge ] The platelet count [At recruitment and daily until discharge ] Haematocrit [At recruitment and daily until discharge ] The prothrombin time (PT) [At recruitment and daily until discharge ] Alanine aminotransferase (ALT) [At recruitment and daily until discharge ] Presence of pleural effusion [At recruitment and daily until discharge ] Serum cholesterol [At recruitment and daily until discharge ] CD 4 counts [Before ingestion of first dose and after completing 3 days of treatment]

Secondary

MeasureTime frame
Duration of hospital stay [At discharge]

Countries

Sri Lanka

Contacts

Public ContactDr. Sanath Hettige

Consultant Family physician

hettiges@sltnet.lk0112851517

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026